Epidemiological trends and implications of breast cancer prevention and control in China and the world:an interpretation of the Global Cancer Statistics Report 2018-2022
Objective To summarize the burden and epidemiological trends of global breast cancer and China's breast cancer according to the 2018,2020 and 2022 versions of the global cancer statistics report jointly prepared by the International Cancer Research Institute of the World Health Organization and the American Cancer Society.Method The data of global and Chinese breast cancer in the 2018,2020,2022 edition of the Global Cancer Statistical Report were analyzed.Results In 2022,the global new breast cancer was estimated to be about 2.309 million,ranking the second.The crude incidence rate of breast cancer was 54.1 per 100 000,and the age standardized incidence rate(ASIR)was 46.8 per 100 000.In 2022,the global breast cancer death would be about 666 000,ranking the fourth,with the crude mortality rate of 11.3 per 100 000,age standardized mortality rate(ASMR)was 12.6 per 100 000.The incidence rate and mortality rate of breast cancer vary greatly between regions/countries,and were related to the human development index;the crude incidence rate was high in economically developed regions,and the crude mortality rate was relatively increasing,but the ASMR was low.In economically underdeveloped areas,the crude incidence rate was relatively low,and the crude mortality rate was relatively decreasing,but ASMR was high.In 2022,the number of breast cancer patients in China would be 357 000,ranking the fourth,with a crude incidence rate of 51.7 per 100 000 and an ASIR of 33.0 per 100 000.In 2022,there would be about 75 000 deaths from breast cancer in China,ranking the seventh,with a crude mortality rate of 10.9 per 100 000 and an ASMR of 6.1 per 100 000.From 2018 to 2022,the incidence rate and mortality rate of breast cancer in China show a downward trend.Conclusions Both the world and China are facing a severe burden of breast cancer,and breast cancer prevention and treatment has a long way to go.
breast cancermorbiditymortalitypreventionrisk factorguide interpretation
NETL
NSTL
万方数据
